Drug recall · January 25, 2017
Risedronate Sodium Delayed-release Tablets recall
Why: Failed Dissolution Specifications
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Risedronate Sodium Delayed-release Tablets, 35 mg, Once-a-Week, 1 tablet per blister (NDC 0093-5509-19), packaged in 4 blisters per carton (NDC 0093-5509-44), Rx only, TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454.
- Lots / codes
Lot # 34027040A; Exp 10/17
- Quantity
- 6,800 cartons
- Company
- Teva Pharmaceuticals USA, North Wales, PA
- Distribution
- Nationwide in the USA and Puerto Rico
- Initiated
- December 1, 2016 · Voluntary: Firm initiated
- Classified
- January 13, 2017
- Reported
- January 25, 2017
- Ended
- June 29, 2017
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Risedronate
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.